Archive · 22 Aug 2025
Tech Entrepreneur's Alzheimer's Risk Reduction Claims
Bryan Johnson, a tech entrepreneur, is using a blood test called Lumipulse G to check for early signs of Alzheimer's disease.
This test looks for a protein in the blood called p-tau 217.
Johnson says his levels of this protein went down after trying a therapy called hyperbaric oxygen therapy.
An expert says that while the blood test is promising, it is not a sure way to diagnose Alzheimer's.
The expert also says it is important to be careful about how often you test and to talk to a doctor to understand what the results mean.
Bryan Johnson claims therapy reduced his Alzheimer's risk marker.
The FDA approved a blood test (Lumipulse G) to detect early Alzheimer's signs.
Lumipulse G identifies the p-tau 217 protein, linked to cognitive decline.
Johnson's p-tau 217 levels decreased 28% with hyperbaric oxygen therapy.
An expert cautions that early markers require professional interpretation.
- Who
- Tech entrepreneur Bryan Johnson, and Dr. Priya Raghavan, a psychiatrist.
- What
- Bryan Johnson claims a therapy lowered an Alzheimer’s risk marker, supported by expert commentary.
- When
- Recently
- Where
- N/A
- Why
- To inform the public about early detection and potential therapies for Alzheimer's disease.
- Test Name
- Lumipulse G
- Protein Measured
- p-tau 217
- Johnson's Baseline
- 0.14
- Johnson's Reduction
- 28%
- Therapy Used
- Hyperbaric Oxygen Therapy